Zacks Research lowered shares of WuXi AppTec (OTCMKTS:WUXAY – Free Report) from a strong-buy rating to a hold rating in a research report released on Monday,Zacks reports.
WuXi AppTec Price Performance
Shares of WUXAY opened at $27.67 on Monday. The firm has a fifty day moving average price of $25.10 and a 200 day moving average price of $19.86. WuXi AppTec has a 1-year low of $12.45 and a 1-year high of $27.80.
About WuXi AppTec
WuXi AppTec is a contract research, development and manufacturing organization (CRDMO) that provides services to pharmaceutical, biotechnology and medical-device companies. Its offerings span the drug-development process, including early-stage discovery, medicinal and synthetic chemistry, biology research, analytical testing, preclinical studies, clinical research support, process development and commercial manufacturing.
The company supports a broad range of therapeutic programs, with capabilities covering small-molecule drugs, biologics, chemical and pharmaceutical products, and cell and gene therapies.
Further Reading
- Five stocks we like better than WuXi AppTec
- Rivian Escapes the EV Graveyard—But Can It Stay Alive?
- Allient’s Data Center and Defense Momentum Is Raising the Stakes
- Constellation Energy’s Google Deal Shows Why Nuclear Uprates Matter for AI
- Lamb Weston’s Turnaround Is Starting to Look Real
Receive News & Ratings for WuXi AppTec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for WuXi AppTec and related companies with MarketBeat.com's FREE daily email newsletter.
